These results suggest a potential prognostic/predictive value of cN-II and should prompt further validation in prospective studies in larger cohorts of patients, that will be crucial to demonstrate whether cN-II could be useful in the clinical setting to personalize chemotherapy in NSCLC patients. This evidence concerns the gene NT5C2 and non-small cell lung carcinoma.